All In Biotech

Drug Trial Radar · NCT01308567

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m^2 and at 20 mg/m^2 in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy

Last checked: Nov 19, 2026Latest source record: Jun 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,168

Actual

Start

May 5, 2011

Primary completion

Sep 2015

Study completion May 2018

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 4, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: * To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m\^2 (Arm A) or 20 mg/m\^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS) in participants with metastatic castration resistant prostate cancer (mCRPC) and not previously treated with chemotherapy. Secondary Objectives: * To evaluate safety in the 3 treatment arms. * To compare efficacy of cabazitaxel at 20 mg/m\^2 and 25 mg/m\^2 to docetaxel for: * Progression Free Survival (PFS) (RECIST 1.1) * Tumor progression free survival (RECIST 1.1) * Tumor response in participants with measurable disease (RECIST 1.1), * PSA response * PSA-Progression free survival (PSA-PFS). * Pain response in participants with stable pain at baseline * Pain progression free survival * Time to occurrence of any skeletal related events (SRE) * To compare Health-Related Quality of Life (HRQL). * To assess the pharmacokinetics and pharmacogenomics of cabazitaxel.

Conditions

  • Prostate Cancer

Interventions

  • Cabazitaxel (XRP6258)Drug

    Pharmaceutical form: Solution for injection; Route of administration: Intravenous

  • Docetaxel (XRP6976)Drug

    Pharmaceutical form: Solution for injection'; Route of administration: Intravenous

  • PrednisoneDrug

    Pharmaceutical form: Tablet; Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months )

Locations

167 sites in 25 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840004

    Muscle Shoals, Alabama

  • Investigational Site Number 840009

    Anaheim, California

  • Investigational Site Number 840014

    Bakersfield, California

  • Investigational Site Number 840030

    Sacramento, California

  • Investigational Site Number 840003

    San Bernardino, California

  • Investigational Site Number 840012

    San Francisco, California

  • Investigational Site Number 840019

    Denver, Colorado

  • Investigational Site Number 840013

    Boca Raton, Florida

  • Investigational Site Number 840035

    Jacksonville, Florida

  • Investigational Site Number 840001

    Port Saint Lucie, Florida

  • Investigational Site Number 840015

    Decatur, Illinois

  • Investigational Site Number 840018

    Wichita, Kansas

  • Investigational Site Number 840010

    Paducah, Kentucky

  • Investigational Site Number 840008

    New Orleans, Louisiana

  • Investigational Site Number 840006

    Rockville, Maryland

  • Investigational Site Number 840238

    Boston, Massachusetts

  • Investigational Site Number 840138

    Boston, Massachusetts

  • Investigational Site Number 840038

    Brookline, Massachusetts

  • Investigational Site Number 840005

    Detroit, Michigan

  • Investigational Site Number 840021

    Saint Louis Park, Minnesota

  • Investigational Site Number 840016

    Kansas City, Missouri

  • Investigational Site Number 840020

    Lincoln, Nebraska

  • Investigational Site Number 840017

    East Orange, New Jersey

  • Investigational Site Number 840033

    Albuquerque, New Mexico

  • Investigational Site Number 840036

    Raleigh, North Carolina

  • Investigational Site Number 840011

    Washington, North Carolina

  • Investigational Site Number 840026

    Akron, Ohio

  • Investigational Site Number 840023

    Cleveland, Ohio

  • Investigational Site Number 840032

    Dunmore, Pennsylvania

  • Investigational Site Number 840007

    Pawtucket, Rhode Island

  • Investigational Site Number 840037

    Myrtle Beach, South Carolina

  • Investigational Site Number 840028

    Chattanooga, Tennessee

  • Investigational Site Number 036016

    Bankstown, Australia

  • Investigational Site Number 036008

    Camperdown, Australia

  • Investigational Site Number 036015

    Coffs Harbour, Australia

  • Investigational Site Number 036001

    Concord, Australia

  • Investigational Site Number 036017

    Fitzroy, Australia

  • Investigational Site Number 036003

    Herston, Australia

  • Investigational Site Number 036010

    Hornsby, Australia

  • Investigational Site Number 036012

    Kurralta Park, Australia

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.